SORT BY

FILTER BY

also on other fortune lists

company facts

f500 stats

Fortune 500

Courtesy of Celgene

224

Celgene

CELG

The biopharmaceutical company is the maker of Thalomid and various other drugs that treat multimple myeloma, inflammatory diseases, and various forms of cancer.

Looking for leads, investment insights, or competitive intelligence?

CEO

Mark J. Alles

CEO Title

Chairman & Chief Executive Officer

Sector

Health Care

Industry

Pharmaceuticals

HQ Location

Summit, N.J.

Years on Fortune 500 List

7

Employees

7,467

Key Financials (Last Fiscal Year)
$ millions% change
Revenues ($M)$13,00315.8%
Profits ($M)$2,940.047.1%
Assets ($M)$30,141
Total Stockholder Equity ($M)$6,921
Market Value — as of March 29, 2018 ($M)$67,102
Profit Ratios
Profit as % of Revenues22.6%
Profits as % of Assets9.8%
Profits as % of Stockholder Equity42.5%
Earnings Per Share (Last Fiscal Year)
Earnings Per Share ($)3.64
EPS % Change (from 2016)46.2%
EPS % Change (5 year annual rate)17.1%
EPS % Change (10 year annual rate)29.7%
Total Return
Total Return to Investors (2017)-9.8%
Total Return to Investors (5 year, annualized)21.6%
Total Return to Investors (10 year, annualized)16.3%
STOCK QUOTE
()0.00 0.00 (0)
  • Previous Close:
  • Market Cap: NaNB
  • Next Earnings Date:
  • High:
  • Low:
  • 52 Week High:
  • 52 Week Low:
  • 52 Week Change %: 0.00
  • P/E Ratio: n/a
  • EPS:
  • Dividend Yield: n/a

News about Celgene

Celgene Boosted Price of Top Cancer Drug on Day of Mega-Deal

Celgene boosted the price of a 10-milligram dose of Revlimid by 3.5% to $719.82 effective Jan. 3.

Read More →
Russian Drugmaker Granted License to Produce Celgene Copycat

Russian drugmaker Nativa got a compulsory license to produce a cheaper version of Celgene's Revlimid.

Read More →